TAK - Halozyme's ENHANZE Product Gets New Patent Grant in EU | Benzinga
Halozyme Therapeutics (NASDAQ: HALO) announced that it has been granted a new patent in the EU that covers the ENHANZE rHuPH20 product, which is produced using the company's proprietary ENHANZE manufacturing methods.
Per the press release, the new patent is included in all of Halozyme's existing and future ENHANZE licenses, meaning that all of its licensees will benefit from this patent. The patent is set to be validated in 37 EU countries, where it will be legally recognized and enforceable, until the expiry date of Mar 6, 2029.
The new patent grant is a significant intellectual property milestone for HALO, ensuring protection and control over its ENHANZE rHuPH20 product across a wide geographical area in the EU until 2029. This enhances the company's competitive edge and provides security for its product and associated technologies.
Shares of the company gained 2.3% in the after-market hours on Jun 5 in response to the encouraging news. Year to date, the stock has jumped 23.5% against the industry's 5.6% decline.
Image Source: Zacks Investment Research
ENHANZE is Halozyme's novel drug delivery technology that facilitates the subcutaneous administration of drugs. The company currently licenses this technology to leading pharmaceutical companies, including Roche (OTC: RHHBY), Takeda (NYSE: TAK), Pfizer (NYSE: